Health and wellness products company USANA Health Sciences (NYSE:USNA) announced better-than-expected results in Q4 FY2023, with revenue down 3% year on year to $221.1 million. On the other hand, the company's full-year revenue guidance of $885 million at the midpoint came in 1.2% below analysts' estimates. It made a GAAP profit of $0.87 per share, improving from its profit of $0.66 per share in the same quarter last year.
Is now the time to buy USANA? Find out by reading the original article on StockStory.
USANA (USNA) Q4 FY2023 Highlights:
- Revenue: $221.1 million vs analyst estimates of $212.4 million (4.1% beat)
- EPS: $0.87 vs analyst estimates of $0.52 (68.9% beat)
- Management's revenue guidance for the upcoming financial year 2024 is $885 million at the midpoint, missing analyst estimates by 1.2% and implying -3.9% growth (vs -7.6% in FY2023)
- Management's EPS guidance for the upcoming financial year 2024 is $2.70 per share at the midpoint, missing analyst estimates of $2.91 (7% miss)
- Gross Margin (GAAP): 80.9%, up from 79.6% in the same quarter last year
- Market Capitalization: $888.2 million
Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences (NYSE:USNA) manufactures and sells nutritional, personal care, and skincare products.
Personal CarePersonal care products include lotions, fragrances, shampoos, cosmetics, and nutritional supplements, among others. While these products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering.
As with other consumer staples categories, personal care brands must exude quality and be priced optimally given the crowded competitive landscape. Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products.
Sales GrowthUSANA is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefitting from better brand awareness and economies of scale.
As you can see below, the company's revenue has declined over the last three years, dropping 6.7% annually. This is among the worst in the consumer staples industry, where demand is typically stable.
This quarter, USANA's revenue fell 3% year on year to $221.1 million but beat Wall Street's estimates by 4.1%. Looking ahead, Wall Street expects revenue to decline 2.7% over the next 12 months.
Key Takeaways from USANA's Q4 Results It was good that revenue, operating margin, and EPS all outperformed expectations this quarter. On the other hand, its full-year revenue and earnings forecast missed analysts' expectations. Overall, this quarter's results were fine but the outlook may cause Wall Street analysts to cut their estimates, which could weigh on the stock. The stock is flat after reporting and currently trades at $47.8 per share.